Takeda Announces Positive Results from Two Pivotal Phase 3 Studies of Oveporexton (TAK-861) in Narcolepsy Type 1

Contributed by: Business Wire

Logo

Business Wire logo

Tags

Health
General Health
Clinical Trials
Research
Science
Pharmaceutical
Biotechnology
Takeda Pharmaceutical Company Limited